KR920700679A - 비(nasal) 전달용 지질부형제와 그 사용법 - Google Patents

비(nasal) 전달용 지질부형제와 그 사용법

Info

Publication number
KR920700679A
KR920700679A KR1019910700796A KR910700796A KR920700679A KR 920700679 A KR920700679 A KR 920700679A KR 1019910700796 A KR1019910700796 A KR 1019910700796A KR 910700796 A KR910700796 A KR 910700796A KR 920700679 A KR920700679 A KR 920700679A
Authority
KR
South Korea
Prior art keywords
excipient
lipid
mono
biologically active
active agent
Prior art date
Application number
KR1019910700796A
Other languages
English (en)
Other versions
KR0157428B1 (ko
Inventor
알란 엘 바이너
Original Assignee
알렌 볼륨
더 리포좀 캄파니 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 볼륨, 더 리포좀 캄파니 인코퍼레이티드 filed Critical 알렌 볼륨
Publication of KR920700679A publication Critical patent/KR920700679A/ko
Application granted granted Critical
Publication of KR0157428B1 publication Critical patent/KR0157428B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

비(nasal)전달용 지질부형제와 그 사용법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 MOPE를 부형제 전달 매개체로 사용할 때 비점막을 통과하는 칼시토닌의 증가를 보여주는 그래프이다. 제2도는 0.1%, 0.2%, 0.4%, 또한 0.8%MOPE 용액과 함께 투여한 인슐린의 비(nasel) 전달을 보여주는 막대 그래프이다.제3도는 데옥시콜레이트와 MOPE에 들어있는 인슐린을 투여한 후 혈중 인슐린농도의 변화를 보여주는 그래프이다.

Claims (22)

  1. 리조인지질로된 무-자극 지질 소포 부형제.
  2. 제1항에 있어서, 리조인지질이 모노-올레오일 포스파티딜 에탄올아민으로된 것인 지질 소포 부형제.
  3. 제2항에 있어서, 모노-올레오일 포스파티딜에탄올아민이 액체나 겔형으로된 것인 부형제.
  4. 제3항에 있어서, 또한 증류수를 포함하는 부형제.
  5. 제4항에 있어서, 모노-올레오일 포스파티딜에탄올아민의 농도가 약 0.1% 내지 0.4%인 부형제.
  6. 제5항에 있어서, pH가 약 8.5 내지 10.0인 부형제.
  7. 제7항에 있어서, pH가 약 9.0인 부형제.
  8. 제7항에 있어서, 또한 생물학적 활성제를 포함하는 부형제.
  9. 제8항에 있어서, 생물학적 활성제가 펩티드인 부형제.
  10. 제9항에 있어서, 펩티드가 인슐린인 부형제.
  11. 제4항에 있어서, 모노-올레오일 포스파티딜에탄올아민의 농도가 약 0.6% 내지 2.0%인 부형제.
  12. 제11항에 있어서, pH가 약 8.5 내지 10.0인 부형제.
  13. 제12항에 있어서, 약 pH9.0인 부형제.
  14. 제13항에 있어서, 또한 생물학적 활성제를 포함하는 부형제.
  15. 제8항에 있어서, 생물학적 활성제가 펩티드인 부형제.
  16. 제9항에 있어서, 펩티드가 칼시토닌인 부형제.
  17. 제3항에 있어서, 화장품인 부형제.
  18. 제17항에 있어서, 또한 생물학적 활성작용제를 포함하는 부형제.
  19. 제3항에 있어서, 염용액을 포함하는 부형제.
  20. 제19항에 있어서, 모노-올레오일 포스파티딜에탄올아민의 농도가 약 0.1% 내지 2.0%인 부형제.
  21. 제20항에 있어서, 약 pH8.5 내지 10.0 인 부형제.
  22. 제21항에 있어서, 약 pH 9.0 인 부형제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910700796A 1989-02-17 1990-02-14 비 전달용 지질부형제와 그 사용법 KR0157428B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31251289A 1989-02-17 1989-02-17
US312.512 1989-02-17
US312512 1989-02-17

Publications (2)

Publication Number Publication Date
KR920700679A true KR920700679A (ko) 1992-08-10
KR0157428B1 KR0157428B1 (ko) 1998-11-16

Family

ID=23211791

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910700796A KR0157428B1 (ko) 1989-02-17 1990-02-14 비 전달용 지질부형제와 그 사용법

Country Status (11)

Country Link
US (1) US5200393A (ko)
EP (1) EP0458894B1 (ko)
JP (1) JPH05500203A (ko)
KR (1) KR0157428B1 (ko)
AT (1) ATE138071T1 (ko)
AU (1) AU639228B2 (ko)
CA (1) CA2045469A1 (ko)
DE (1) DE69027022T2 (ko)
DK (1) DK0458894T3 (ko)
ES (1) ES2089011T3 (ko)
WO (1) WO1990009385A1 (ko)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891466A (en) * 1990-08-13 1999-04-06 Yesair; David W. Mixed Liped-Bicarbonate colloidal particles for delivering drugs or calories
US6419850B1 (en) * 1991-06-03 2002-07-16 Airel-West System and composition for decontaminating fluids
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
DE69530519T2 (de) 1994-12-22 2004-03-04 Astrazeneca Ab Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
EE9700138A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US7070799B1 (en) 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US20030059440A1 (en) * 1998-09-01 2003-03-27 Tim Clarot Composition and method for moisturizing nasal tissue
ES2173679T3 (es) * 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
CA2368655A1 (en) * 1999-04-08 2000-10-19 Gregory M. Glenn Dry formulation for transcutaneous immunization
EP1187639A1 (en) 1999-06-04 2002-03-20 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6489312B1 (en) * 1999-06-15 2002-12-03 Medimmune Oncology, Inc. Pharmaceutical formulations comprising aminoalkyl phosphorothioates
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6432383B1 (en) 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
WO2002054996A2 (en) * 2000-10-23 2002-07-18 Euro Celtique Sa Terazosin transdermal device and methods
DK1372708T3 (da) * 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
KR20030065965A (ko) * 2002-02-02 2003-08-09 주식회사 두산 리소포스파티딜에탄올아민을 유효성분으로 함유하는 피부미백용 조성물
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
ES2295647T3 (es) * 2002-07-15 2008-04-16 Alcon, Inc. Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
US9358296B2 (en) 2003-02-24 2016-06-07 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
JP5475215B2 (ja) * 2003-02-24 2014-04-16 ファーマシューティカル プロダクションズ， インコーポレイテッド 経粘膜薬物送達システム
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
AU2006255177A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
US20090093019A1 (en) * 2007-04-27 2009-04-09 Phelps Jamie P Production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2009117401A2 (en) * 2008-03-21 2009-09-24 Elan Pharama International Limited Compositions for site-specific delivery of imatinib and methods of use
JP5341532B2 (ja) * 2009-01-19 2013-11-13 第一電子工業株式会社 １対の誤嵌合防止キー及び該キーを用いた電気コネクタ
DE102009008094A1 (de) 2009-02-09 2010-08-19 Barnikol-Keuten, Doris, Dr. In situ Haft-Gelbildende Zubereitungen, insbesondere zur topischen Anwendung auf befeuchtete Haut/Schleimhaut
CZ308596B6 (cs) * 2017-04-03 2020-12-23 Ústav molekulární genetiky AV ČR, v. v. i. Deriváty fosfolipidů a jejich použití jako léčiva

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159988A (en) * 1974-08-06 1979-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Synthetic phospholipids, a process for their manufacture and their use
GB2051574B (en) * 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
DE3171774D1 (en) * 1980-03-31 1985-09-19 Teijin Ltd Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
US4619795A (en) * 1984-12-24 1986-10-28 Technicon Instruments Corp. Method for preparing lipid vesicles
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US4923854A (en) * 1986-01-22 1990-05-08 The Liposome Company, Inc. Solubilization of hydrophobic materials using lysophospholipid
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
CA1335076C (en) * 1987-04-01 1995-04-04 Hanna R. Kowarski Pharmaceutical composition and method for intranasal administration
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system

Also Published As

Publication number Publication date
KR0157428B1 (ko) 1998-11-16
ES2089011T3 (es) 1996-10-01
DE69027022D1 (de) 1996-06-20
DK0458894T3 (da) 1996-10-07
EP0458894A4 (en) 1991-10-01
EP0458894A1 (en) 1991-12-04
JPH05500203A (ja) 1993-01-21
AU5173690A (en) 1990-09-05
ATE138071T1 (de) 1996-06-15
WO1990009385A1 (en) 1990-08-23
EP0458894B1 (en) 1996-05-15
CA2045469A1 (en) 1990-08-18
US5200393A (en) 1993-04-06
DE69027022T2 (de) 1996-11-28
AU639228B2 (en) 1993-07-22

Similar Documents

Publication Publication Date Title
KR920700679A (ko) 비(nasal) 전달용 지질부형제와 그 사용법
RU2218935C2 (ru) Стабильные концентрированные препаративные формы инсулина для доставки через легкие
ES2304969T3 (es) Composiciones anticonvulsivas transnasales.
ATE92931T1 (de) Fluor- und phosphorhaltige amphiphilische molekuele mit oberflaechenaktiven eigenschaften.
DE69428040D1 (de) Orale darreichungsform
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
CA2141026C (en) Pharmaceutical compositions for transmucosal delivery of peptides
EP0358234A2 (en) Intranasal calcitonin formulations
US5759566A (en) Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
US5654000A (en) Pharmaceutical compositions for transmucosal delivery of peptides
KR870007704A (ko) 향상된 생체학적 허용도를 갖는 투약시스템(Drug Delivery System)
KR960702847A (ko) 생물학적 활성의 바소프레신 유사체
ATE364391T1 (de) Arzneiformulierung enthaltend ciclosporin und deren verwendung
BR9612040A (pt) Lipossomas liofilizados contendo pge-1 para uso no tratamento de disfunção da ereção
RU2292219C2 (ru) Фармацевтический компонент на основе паратиреоидного гормона человека и содержащая его фармацевтическая композиция для интраназального применения
NO883468D0 (no) Fremgangsmaate til fremstilling av farmasoeytiske blandinger inneholdende cyklopeptider som reserpsjonsbefordrere ved applikasjon paa slimhuden.
KR100466757B1 (ko) 생체에 펩티드성 약물을 유입시키기 위한 국소 제제
BRPI0808733A2 (pt) Uso de uma microemulsão aquosa para a preparação de uma formulação para o tratamento de doença adiposas
De Ponti et al. Use of chemical enhancers for nasal drug delivery
RU94010496A (ru) Ноотропное средство и лекарственный состав ноотропного средства
Pr̂íborský et al. The influence of detergents on skin barrier properties
KR0178422B1 (ko) 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀
KR890000116B1 (ko) 피부치료를 위한 국소투여용 조성물
GB763168A (en) Inhalant preparation
RU98109592A (ru) Применение белка s-100b в лекарственных средствах и лекарственные средства, содержащие белок s-100b

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050801

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee